Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development

On June 24, 2024, Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research  (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo).  The two parties will engage in comprehensive and in-depth collaboration in multiple fields, including animal electrocardiogram diagnostics and personnel training, as well as animal ophthalmic disease diagnosis and model establishment, to jointly promote the development of innovative drugs.

Complementary advantages drive improvement; working together to empower new capabilities
 Supporting the development of cardiovascular and ophthalmic disease drugs

Hetuo is a CRO specializing in preclinical pharmacodynamic evaluation, focusing on translational medicine platform technologies, and actively promoting the industrialization of medicine.  The company adheres to GLP standards, implementing scientific management of projects to ensure the authenticity, accuracy/scientific integrity, and consistency of research and development results.  Currently, Hetuo has successfully developed animal models covering cardiovascular, neurological, gastrointestinal, ophthalmic, dermatological, metabolic, and urinary system diseases. The company offers customized research services and has established three leading pharmacodynamic evaluation platforms, particularly in the fields of neurological disorders, ophthalmic diseases, and cardiovascular system drugs.

Medicilon, relying on two decades of extensive experience in the preclinical research field of biopharmaceutical, provides one-stop new drug R&D services that meet domestic and international regulatory standards, covering drug discovery, pharmaceutical research, and preclinical research. Medicilon's expertise spans cutting-edge areas such as bispecific/multispecific antibodies, antibody-drug conjugates (ADC), mRNA vaccines, small nucleic acid drugs, protein degradation targeting chimeras (PROTAC), and cell and gene therapy (CGT).  Currently, Medicilon has successfully assisted 480 IND applications in entering clinical trials approved by China's NMPA, the US FDA, the EU EMA, and Australia TGA.

This collaboration stems from both parties' deep insights into the trends in innovative drug development and their shared mission to empower the innovation process in pharmaceutical R&D.  After discussions and exchanges, both parties have signed a collaboration agreement on training and services for experimental animal electrocardiogram diagnostics. We believe that with deep collaboration and complementary strengths, we can provide clients with higher quality and more efficient R&D services for cardiovascular drugs and ophthalmic disease drugs, facilitating the early entry of innovative drugs into clinical trials for our clients.

It is worth mentioning that on the afternoon of June 23rd, Dr. Xiarong Sun, Project Director of Hetuo, participated as a keynote speaker at the General Training on Experimental Animal Electrocardiography Basics, Chinese Academy of Sciences held jointly by the Shanghai Experimental Animal Society and MPR. Dr. Sun shared his professional experience and skills and was highly praised by the attendees.  As the collaboration deepens between both parties, the Hetuo team will continue to provide progressive professional training for MPR, further enhancing industry expertise and service quality.

This collaboration represents a joint commitment from both sides to empower pharmaceutical innovation and reflects a steadfast confidence in the future of drug research and development innovation.  Medicilon will join hands with Hetuo to face challenges together, explore opportunities, and provide strong support in exploring new therapeutic areas and methods for clients!

About Hetuo

Hetuo Innovation, as a CRO service company specializing in preclinical efficacy evaluation of pharmaceutical products, provides pharmacology evaluation services to global pharmaceutical R&D companies and research institutes.  Hetuo adheres to GLP (Good Laboratory Practice) standards, ensuring the scientific management and implementation of projects to guarantee the authenticity, scientific validity, and consistency of research and development results.  Currently, Hetuo has developed animal models for cardiovascular, neurological, digestive, ophthalmic, dermatological, metabolic, and urological diseases. They offer customized animal model establishment and research services tailored to specific research needs.  Hetuo aims to provide scalable, standardized, highly regulated, and reliable services, shortening the drug and medical device development cycles for global clients, reducing development costs and risks. Upholding the company mission, Hetuo contributes to pharmaceutical R&D, paving the way for a healthier future.